newsPhase II study of opicinumab in MS misses primary endpoint7 June 2016 | By Victoria White, Digital Content ProducerThe primary endpoint primary endpoint was a multicomponent measure evaluating improvement of physical function, cognitive function, and disability...
newsDaclizumab demonstrates significant improvements in cognition in RRMS22 April 2016 | By Victoria White, Digital Content ProducerNew data demonstrates daclizumab’s positive cognitive outcomes and safety profile in patients with relapsing-remitting multiple sclerosis (RRMS)...
newsTecfidera demonstrates sustained efficacy in RRMS studies18 April 2016 | By Victoria White, Digital Content ProducerBiogen has unveiled new Tecfidera research that reinforces its sustained efficacy in newly diagnosed relapsing-remitting multiple sclerosis patients...
newsEncouraging top-line interim results for RHB-104 in RRMS5 April 2016 | By Victoria WhiteRedHill has announced encouraging top-line interim results from its CEASE-MS study of RHB-104 in patients with relapsing-remitting multiple sclerosis...
newsCelgene announces 72-week study results for ozanimod in MS18 February 2016 | By Victoria WhiteReductions in brain lesions at week 24 were maintained while relapses were further reduced at week 72 with continuous ozanimod treatment...
newsBreakthrough Therapy Designation for ocrelizumab in PPMS17 February 2016 | By Victoria WhiteRoche's ocrelizumab is the first investigational medicine to receive Breakthrough Therapy Designation in multiple sclerosis...
newsMS treatment, AHSCT, shows “remarkable” results18 January 2016 | By Victoria WhiteAutologous haematopoietic stem cell transplantation (AHSCT), developed at Sheffield Teaching Hospitals, has shown 'remarkable' results in patients with MS...
newsBiogen reports top-line results of natalizumab SPMS study21 October 2015 | By Victoria WhiteThe Phase 3 ASCEND study investigating natalizumab in the treatment of secondary progressive multiple sclerosis did not achieve its primary and secondary endpoints...
newsOcrelizumab signficantly reduces disability progression in MS in studies9 October 2015 | By Victoria WhiteRoche’s Chief Medical Officer said the results of the pivotal trials have the potential to transform the treatment of MS...
newsLemtrada treatment effects maintained over five years in RRMS8 October 2015 | By Victoria WhiteLemtrada targets CD52, a protein abundant on T and B cells. Circulating T and B cells are thought to be responsible for the damaging inflammatory process in MS...
newsNovartis releases long-term efficacy results for Gilenya in MS8 October 2015 | By Victoria WhiteThe analysis evaluated the proportion of Gilenya patients achieving 'no evidence of disease activity' (NEDA-4) every year over seven years...
newsMultiple sclerosis therapeutics market to reach $20b by 20247 October 2015 | By Victoria WhiteThe value of the multiple sclerosis therapeutics market will rise slowly from $17.2 billion in 2014 to approximately $20 billion by 2024...
newsNew data shows sustained efficacy of Tecfidera in RRMS7 October 2015 | By Victoria WhiteBiogen is to present the data at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)...
newsNew data suggests Aubagio slows brain atrophy in RMS7 October 2015 | By Victoria WhiteMRI data from Genzyme’s Phase III TEMSO study demonstrate that Aubagio significantly slowed brain atrophy in people with relapsing multiple sclerosis (RMS)...
newsEnrolment completes for Phase IIa trial of ATX-MS-14676 August 2015 | By Victoria WhiteApitope today announced that its partner, Merck Serono, has completed patient enrolment for the Phase IIa study of ATX-MS-1467 (also known as M2736)...
